diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 329db7879..dd5c26523 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -35,6 +35,12 @@ The Cell Press review characterizes GLP-1s as marking a 'system-level redefiniti MA plans' near-universal prior authorization creates administrative friction that may worsen the already-poor adherence rates for GLP-1s. PA requirements ensure only T2D-diagnosed patients can access, effectively blocking obesity-only coverage despite FDA approval. This access restriction compounds the chronic-use economics challenge by adding administrative barriers on top of existing adherence problems. + +### Additional Evidence (challenge) +*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16* + +Aon's real-world data challenges the 'inflationary through 2035' thesis by showing medical cost growth for GLP-1 users drops to 2% after 12 months versus 6% for non-users, with diabetes patients showing 6-9 percentage point lower cost growth at 30 months. The net impact depends entirely on payer time horizon: short-term payers see inflation, long-term risk-bearers see deflation. The 'inflationary' conclusion may be an artifact of analyzing systems dominated by short-term payment models rather than an inherent property of the drugs. + --- Relevant Notes: diff --git a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md index 8dab4f1bd..f11c5e28d 100644 --- a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md +++ b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md @@ -36,6 +36,12 @@ For value-based care models and capitated payers, this multi-organ protection cr SELECT trial exploratory analysis (N=17,604, median 41.8 months) shows semaglutide reduces ALL-CAUSE hospitalizations by 10% (18.3 vs 20.4 per 100 patient-years, P<.001) and total hospital days by 11% (157.2 vs 176.2 days per 100 patient-years, P=.01). Critically, benefits extended beyond cardiovascular causes to total hospitalization burden, suggesting systemic effects across multiple organ systems. + +### Additional Evidence (extend) +*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16* + +Aon data adds cancer risk reduction to the multi-organ protection profile: female users showed ~50% lower ovarian cancer incidence and 14% lower breast cancer incidence, plus lower rates of osteoporosis and rheumatoid arthritis. The sex-differential in MACE reduction (47% for women vs 26% for men) suggests protective mechanisms may be stronger or more diverse in women. This expands the value proposition beyond the kidney and cardiovascular endpoints already documented. + --- Relevant Notes: diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index 1f412e7f8..b2b463452 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -47,6 +47,12 @@ This data comes from commercially insured populations (younger, fewer comorbidit No data yet on whether payment model affects persistence—does being in an MA plan with care coordination improve adherence vs. fee-for-service? This is directly relevant to value-based care design. + +### Additional Evidence (extend) +*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16* + +Aon data shows adherence is the binding variable for GLP-1 cost-effectiveness: the 80%+ adherent cohort shows dramatically stronger effects across all outcomes. For diabetes patients, medical cost growth at 30 months is 6 points lower overall but 9 points lower with 80%+ adherence. For weight loss patients, cost growth is 3 points lower at 18 months but 7 points lower with consistent use. This suggests the low persistence rates documented elsewhere may be the primary barrier to realizing GLP-1 value, not the drug efficacy itself. + --- Relevant Notes: diff --git a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md index c8aa03417..789e846f6 100644 --- a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md +++ b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md @@ -37,6 +37,12 @@ At $245/month list price, even modest copays ($50-100/month) create a sustained The source does not provide granular income-stratified discontinuation rates, so the magnitude of the effect is unclear. It's possible income is a proxy for other factors (health literacy, access to care coordination, baseline health status) rather than affordability per se. + +### Additional Evidence (confirm) +*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16* + +Aon's finding that benefits scale dramatically with adherence (80%+ adherent cohort shows strongest effects across all outcomes) provides the mechanism for why affordability-driven discontinuation is so costly: the patients who stop due to cost are precisely those who would benefit most from continued use, and the savings only materialize after 12-18 months of consistent use. + --- Relevant Notes: diff --git a/inbox/archive/.extraction-debug/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.json b/inbox/archive/.extraction-debug/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.json new file mode 100644 index 000000000..183fb0408 --- /dev/null +++ b/inbox/archive/.extraction-debug/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.json @@ -0,0 +1,32 @@ +{ + "rejected_claims": [ + { + "filename": "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-medical-savings-lag-drug-costs-by-12-18-months.md", + "issues": [ + "missing_attribution_extractor" + ] + }, + { + "filename": "glp-1-receptor-agonists-reduce-female-cancer-incidence-by-14-50-percent-suggesting-multi-organ-protective-mechanisms-beyond-metabolic-effects.md", + "issues": [ + "missing_attribution_extractor" + ] + } + ], + "validation_stats": { + "total": 2, + "kept": 0, + "fixed": 2, + "rejected": 2, + "fixes_applied": [ + "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-medical-savings-lag-drug-costs-by-12-18-months.md:set_created:2026-03-16", + "glp-1-receptor-agonists-reduce-female-cancer-incidence-by-14-50-percent-suggesting-multi-organ-protective-mechanisms-beyond-metabolic-effects.md:set_created:2026-03-16" + ], + "rejections": [ + "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-medical-savings-lag-drug-costs-by-12-18-months.md:missing_attribution_extractor", + "glp-1-receptor-agonists-reduce-female-cancer-incidence-by-14-50-percent-suggesting-multi-organ-protective-mechanisms-beyond-metabolic-effects.md:missing_attribution_extractor" + ] + }, + "model": "anthropic/claude-sonnet-4.5", + "date": "2026-03-16" +} \ No newline at end of file diff --git a/inbox/archive/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md b/inbox/archive/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md index 0caf70348..b1f012f45 100644 --- a/inbox/archive/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md +++ b/inbox/archive/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md @@ -7,9 +7,13 @@ date: 2026-01-13 domain: health secondary_domains: [internet-finance] format: report -status: unprocessed +status: enrichment priority: high tags: [glp-1, employer-costs, cancer-risk, cardiovascular, cost-offset, real-world-evidence] +processed_by: vida +processed_date: 2026-03-16 +enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -49,3 +53,14 @@ WHY ARCHIVED: The temporal cost dynamics (costs up Y1, down Y2+) are the most im EXTRACTION HINT: Focus on the temporal cost curve and what it implies for different payment models. The cancer finding is separately important but preliminary. flagged_for_rio: ["GLP-1 cost dynamics have direct implications for health investment thesis — long-term risk-bearers capture savings that short-term payers miss"] + + +## Key Facts +- Aon analyzed 192,000+ GLP-1 users in U.S. commercial health claims data +- First 12 months on Wegovy/Zepbound: medical costs rise 23% vs 10% for non-users +- After 12 months: medical costs grow 2% vs 6% for non-users +- Diabetes indication at 30 months: medical cost growth 6 points lower, 9 points lower with 80%+ adherence +- Weight loss indication at 18 months: cost growth 3 points lower, 7 points lower with consistent use +- Female GLP-1 users: ~50% lower ovarian cancer incidence, 14% lower breast cancer incidence +- Adherent users (80%+): 47% MACE reduction for women, 26% for men +- Study released January 13, 2026